Module 1: Photosafety Evaluation: Why, When, and How to Conduct?

Recorded On: 02/27/2025

image
image


Phototoxic properties of systemically applied pharmaceuticals may be the cause of serious adverse drug reactions. Despite being clinically manageable in principle, they can limit the use of a drug depending on the indication. Protective measures against sunlight can be applied very reasonably during a few days but may not be practicable for chronic treatments. Thus, both patients and health authorities are unlikely to accept a relevant photosensitization risk in such situations.

Since the global adoption of ICH S10 “Photosafety Evaluation of Pharmaceuticals” in 2013, both the industry and CROs have gained significant experience in conducting risk assessment for phototoxicity potentials for pharmaceuticals. However, it still requires an individual project toxicologist to consider various aspects of a pharmaceutical program to have a staged and integrated analysis of the risk.

Also, special experience and equipment are needed to conduct compliant studies, for which most of the toxicologists lack hands-on experience. This module focuses on providing details on the in vitro and in vivo studies as part of a tiered testing strategy and providing the scenarios and principles to guide an integrated human risk assessment.

Daniel Bauer, PhD

Daniel Bauer, PhD

Director of Preclinical Safety

Novartis

Dr. Daniel Bauer is Director of Preclinical Safety at Novartis in Basel, Switzerland. He is a trained chemist and a board-certified toxicologist with over 20 years of experience in the pharmaceutical industry. Dr. Bauer began his career at Novartis as a lab head in molecular and cellular toxicology, later specializing in photosafety evaluation with a focus on tiered testing strategies from in vitro to in vivo to clinical translation.

As a study director and monitor, Dr. Bauer has contributed to numerous in vitro safety screening studies, including phototoxicity and genetic toxicity, during candidate selection. He has also supervised in vitro phototoxicity studies under GLP. Currently, he serves as Global Expert in Photosafety, overseeing all photosafety activities at Novartis.

For EFPIA, Dr. Bauer was a member of the ICH S10 Expert Working Group representing the European pharmaceutical industry. He is currently the chair of the EFPIA Photosafety Working Group, where he facilitates industry-wide knowledge exchange and new initiatives.

In addition, Dr. Bauer acts as a project toxicologist, working on topical and oral FIH projects in dermatology and oncology indications.

Key:

Complete
Failed
Available
Locked
Module 1:Photosafety Evaluation: Why, When, and How to Conduct?
Module 1: Photosafety Evaluation: Why, When, and How to Conduct?, Daniel Bauer, PhD
Recorded 02/27/2025  |  90 minutes
Recorded 02/27/2025  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.